Cancer Family
Hematopoietic and Lymphatic System Neoplasm
CI-CAN-00000022Explore in graph →
Non-malignant4,304 active trials98 approved drugs1,010 evidence items
- NCIt
- C35813
Loading cancer entity…
Cancer Family
CI-CAN-00000022Explore in graph →
Clinical trials
18,827 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06375044 | Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma | recruiting | Phase 1 | 130 | Jiangsu Simcere Pharmaceutical Co., Ltd.INDUSTRY | 2 | Aug 28, 2026 | clinicaltrials |
| NCT06690827 | Clinical Trial of CD123-targeted CAR-NK Therapy for Relapse/Refractory AML or BPDCN | recruiting | Phase 1 | 30 | Chongqing Precision Biotech Co., LtdINDUSTRY | 1 | Aug 28, 2026 | clinicaltrials |
| NCT07075185 | A Study to Evaluate a Novel Gene Therapy in Patients With Relapsed and Refractory Multiple Myeloma(inMMyCAR) | recruiting | Phase 1 | 70 | Kelonia Therapeutics, Inc.INDUSTRY | 2 | Aug 28, 2026 | clinicaltrials |
| NCT07123454 | A Phase I/II Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma(Lumi-NHL) | recruiting | Phase 1 / Phase 2 | 91 | AstraZenecaINDUSTRY | 8 | Aug 28, 2026 | clinicaltrials |
| NCT07257419 | CD45RA-depleted CD19-CAR T Cell Consolidation After TCRαβ+/CD19 B Cell-depleted Haploidentical Hematopoietic Cell Transplantation for Relapsed/Refractory CD19+ ALL and Lymphoma | recruiting | Phase 1 | 70 | St. Jude Children's Research HospitalOTHER | 1 | Aug 28, 2026 | clinicaltrials |
| NCT07520006 | Study of NX-5948 in Combination With Other Agents in Adults With B-cell Malignancies | recruiting | Phase 1 / Phase 2 | 150 | Nurix Therapeutics, Inc.INDUSTRY | 1 | Aug 28, 2026 | clinicaltrials |
| NCT05623982 | A Study of GNC-038 Injection in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma | recruiting | Phase 1 / Phase 2 | 40 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Aug 27, 2026 | clinicaltrials |
| NCT05836896 | A Phase I Trial to Establish the Safety and Maximum Tolerated Dose of High-affinity Autologous BCMA-targeting Chimeric Antigen Receptor (CAR) T-cells in Patients With Relapsed and Refractory B-cell Malignancies(CARLOTTA01) | recruiting | Phase 1 | 16 | Technische Universität DresdenOTHER | 1 | Aug 27, 2026 | clinicaltrials |
| NCT06066203 | A Study of GNC-035 in Relapsed or Refractory Non-Hodgkin 's Lymphoma and Other Hematological Malignancies | recruiting | Phase 1 / Phase 2 | 40 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Aug 27, 2026 | clinicaltrials |
| NCT06383338 | A Study Investigating the Change in Metabolism Phenotype in Paediatric, Adolescent & Young Adults With Hodgkin or Non-Hodgkin Lymphoma.(PEGASUS) | recruiting | Phase 1 | 10 | Murdoch Childrens Research InstituteOTHER | 1 | Aug 27, 2026 | clinicaltrials |
| NCT07681596 | A Modular, Phase I/II, Multicentre Study to Evaluate AZD4045, in Participants With Relapsed or Refractory Multiple Myeloma | recruiting | Phase 1 / Phase 2 | 101 | AstraZenecaINDUSTRY | 2 | Aug 27, 2026 | clinicaltrials |
| NCT05495035 | Study for Safety and Efficacy of Olverembatinib Combined With APG-2575 in Children With Relapsed/Refractory Ph + ALL | recruiting | Phase 1 | 19 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Aug 26, 2026 | clinicaltrials |
| NCT05857969 | Ex Vivo Drug Sensitivity Testing and Multi-Omics Profiling | recruiting | Phase 1 | 65 | Florida International UniversityOTHER | 1 | Aug 26, 2026 | clinicaltrials |
| NCT06227026 | Pilot Study of Anti-CD19 Chimeric Antigen Receptor T Cells (CAR-T Cells) for the Treatment of Relapsed/Refractory CD19+ Malignancies(PRODIGY) | recruiting | Phase 1 | 10 | University of UtahOTHER | 1 | Aug 26, 2026 | clinicaltrials |
| NCT06834282 | CER-1236 in Patients With Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), and Myelofibrosis (MF)(CertainT-1) | recruiting | Phase 1 | 18 | CERo Therapeutics Holdings, Inc.INDUSTRY | 1 | Aug 26, 2026 | clinicaltrials |
| NCT07439211 | Assessing PI3K Gamma Inhibition With Azacitidine, Venetoclax and Eganelisib in Patients With Acute Myeloid Leukemia(GAVEL) | recruiting | Phase 1 | 48 | Jacqueline Garcia, MDOTHER | 1 | Aug 26, 2026 | clinicaltrials |
| NCT07691606 | A Study of ARC-02 in B-cell NHL(ABLATE-101) | recruiting | Phase 1 | 140 | Taiho Oncology, Inc.INDUSTRY | 6 | Aug 26, 2026 | clinicaltrials |
| NCT07788118 | A Phase Ib/II Exploratory Clinical Trial of Memory-Enhanced 7×19-THEMIS CAR-T Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma | recruiting | Phase 1 / Phase 2 | 70 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Aug 26, 2026 | clinicaltrials |
| NCT04851119 | Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors | recruiting | Phase 1 / Phase 2 | 147 | Children's Oncology GroupNETWORK | 1 | Aug 25, 2026 | clinicaltrials |
| NCT05389423 | Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas | recruiting | Phase 1 | 25 | National Cancer Institute (NCI)NIH | 1 | Aug 25, 2026 | clinicaltrials |
| NCT05826535 | Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma | recruiting | Phase 1 / Phase 2 | 270 | Lyell Immunopharma, Inc.INDUSTRY | 2 | Aug 25, 2026 | clinicaltrials |
| NCT05886049 | A Phase 1b Study of Menin Inhibitor SNDX- 5613 in Combination With Daunorubicin and Cytarabine in Newly Diagnosed Patients With Acute Myeloid Leukemia and NPM1 Mutated/FLT3 Wildtype or MLL/KMT2A Rearranged or NUP98 Alterations Disease | recruiting | Phase 1 | 38 | National Cancer Institute (NCI)NIH | 1 | Aug 25, 2026 | clinicaltrials |
| NCT06247787 | A Study to Find the Highest Dose of Imetelstat in Combination With Fludarabine and Cytarabine for Patients With AML, MDS or JMML That Has Come Back or Does Not Respond to Therapy | recruiting | Phase 1 | 36 | Children's Oncology GroupNETWORK | 1 | Aug 25, 2026 | clinicaltrials |
| NCT06533761 | Eganelisib as Monotherapy and in Combination With Cytarabine in Relapsed/Refractory AML | recruiting | Phase 1 | 125 | Stelexis BioSciencesINDUSTRY | 2 | Aug 25, 2026 | clinicaltrials |
| NCT06536049 | Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma | recruiting | Phase 1 / Phase 2 | 38 | Yazeed SawalhaOTHER | 1 | Aug 25, 2026 | clinicaltrials |
| NCT06087653 | Safety, Efficacy, and Pharmacokinetics of Continuous Subcutaneous Lenalidomide in Multiple Myeloma (MM) | recruiting | Phase 1 / Phase 2 | 24 | Starton Therapeutics, IncINDUSTRY | 1 | Aug 24, 2026 | clinicaltrials |
| NCT06158828 | Pilot Study of Memory-like Natural Killer (ML NK) Cells After TCRαβ T Cell Depleted Haploidentical Transplant in AML(ABCD-NK) | recruiting | Phase 1 / Phase 2 | 68 | Washington University School of MedicineOTHER | 1 | Aug 24, 2026 | clinicaltrials |
| NCT07220616 | A First-in-Human Trial of DS3790a in Participants With Hematological Malignancies | recruiting | Phase 1 / Phase 2 | 420 | Daiichi SankyoINDUSTRY | 4 | Aug 24, 2026 | clinicaltrials |
| NCT05263284 | 8-Chloroadenosine in Combination With Venetoclax for the Treatment of Patients With Relapsed/Refractory Acute Myeloid Leukemia | recruiting | Phase 1 | 30 | City of Hope Medical CenterOTHER | 1 | Aug 21, 2026 | clinicaltrials |
| NCT05294731 | Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader | recruiting | Phase 1 / Phase 2 | 146 | BeiGeneINDUSTRY | 1 | Aug 21, 2026 | clinicaltrials |
| NCT07573111 | Study of QUAIL-100 in Pediatric and Young Adult Participants With High-Risk Hematologic Malignancies Who Have Received a Hematopoietic Stem Cell Transplantation | recruiting | Phase 1 | 12 | Laguna Biotherapeutics, Inc.INDUSTRY | 1 | Aug 21, 2026 | clinicaltrials |
| NCT05110742 | Phase I/II Study of CD5 CAR Engineered IL15-Transduced Cord Blood-Derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapsed/Refractory Hematological Malignances | recruiting | Phase 1 / Phase 2 | 64 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT05579132 | A Clinical Study of MK-1045 (CN201) in People With Precursor B-cell Acute Lymphoblastic Leukemia (MK-1045-002) | recruiting | Phase 1 / Phase 2 | 203 | MSD R&D (China) Co., Ltd.INDUSTRY | 1 | Aug 20, 2026 | clinicaltrials |
| NCT06001788 | Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia | recruiting | Phase 1 | 171 | Kura Oncology, Inc.INDUSTRY | 3 | Aug 20, 2026 | clinicaltrials |
| NCT06066359 | Ph I/II Trial of Cord Blood-derived NK Cells With NY-ESO-1 TCR/IL-15 for R/R Myeloma | recruiting | Phase 1 / Phase 2 | 44 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT06495723 | Polyspecific Antibodies in Lymphoproliferative T-cell Disorders(PALT1) | recruiting | Phase 1 / Phase 2 | 54 | Xenothera SASINDUSTRY | 2 | Aug 20, 2026 | clinicaltrials |
| NCT06678659 | A Study of REC-1245 in Participants With Unresectable, Locally Advanced, or Metastatic Cancer(DAHLIA) | recruiting | Phase 1 / Phase 2 | 170 | Recursion Pharmaceuticals Inc.INDUSTRY | 2 | Aug 20, 2026 | clinicaltrials |
| NCT07775508 | In Vivo CD19/CD20 CAR T-Cell Therapy for Relapsed/Refractory B-Cell Lymphoma | recruiting | Phase 1 | 18 | Chinese PLA General HospitalOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT04104776 | A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas | recruiting | Phase 1 / Phase 2 | 300 | Novartis PharmaceuticalsINDUSTRY | 7 | Aug 19, 2026 | clinicaltrials |
| NCT05011422 | Haploidentical Hematopoietic Stem Cell Transplantation With Ex Vivo TCR Alpha/Beta and CD19 Depletion in Pediatric Hematologic Malignancies | recruiting | Phase 1 | 50 | Washington University School of MedicineOTHER | 1 | Aug 19, 2026 | clinicaltrials |
| NCT05145816 | Phase 1/2a Study of Belantamab Mafodotin in Relapsed or Refractory AL Amyloidosis | recruiting | Phase 1 / Phase 2 | 37 | University of Texas Southwestern Medical CenterOTHER | 1 | Aug 19, 2026 | clinicaltrials |
| NCT05714839 | A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments(DynaMMic-1) | recruiting | Phase 1 / Phase 2 | 123 | GlaxoSmithKlineINDUSTRY | 13 | Aug 19, 2026 | clinicaltrials |
| NCT06106945 | AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Multiple Myeloma | recruiting | Phase 1 / Phase 2 | 226 | AstraZenecaINDUSTRY | 9 | Aug 19, 2026 | clinicaltrials |
| NCT06137118 | AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia(SYRUS) | recruiting | Phase 1 / Phase 2 | 255 | AstraZenecaINDUSTRY | 13 | Aug 19, 2026 | clinicaltrials |
| NCT06399640 | Eltanexor and Venetoclax in Relapsed or Refractory Myelodysplastic Syndrome and Acute Myeloid Leukemia | recruiting | Phase 1 | 60 | Vanderbilt-Ingram Cancer CenterOTHER | 1 | Aug 19, 2026 | clinicaltrials |
| NCT06569147 | Elranatamab in Patients With Relapsed or Refractory AL Amyloidosis | recruiting | Phase 1 / Phase 2 | 49 | Dana-Farber Cancer InstituteOTHER | 1 | Aug 19, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Aug 28, 2026source: clinicaltrials